Article
Association of single nucleotide polymorphisms of cytochrome P450 enzymes with experience of vasomotor, vaginal and musculoskeletal symptoms among breast cancer patients: a systematic review.
BMC cancer - 18 May 2021
Chan Carmen W H, Law Bernard M H, Ng Marques S N, Wong Corinna C Y, Wong Carissa W Y, Quinley Morgan, Orgusyan Jessica M, Chow Ka Ming, Waye Mary M Y
Abstract excerpt
BACKGROUND: Adjuvant endocrine therapies are known to induce undesirable adverse effects such as vasomotor, vaginal and musculoskeletal symptoms among breast cancer patients. Drugs used in these therapies are often metabolised by cytochrome P450 (CYP) enzymes, in which their metabolising activities can be modified by single nucleotide polymorphisms (SNP) in CYP genes and CYP genotypes. This review aims to explore...
Topics
- Antineoplastic Agents, Hormonal
- Arthralgia
- Atrophy
- Breast Neoplasms
- Chemotherapy, Adjuvant
- Cytochrome P-450 Enzyme System
- Estrogen Antagonists
- Estrogens
- Female